Science & Programs
Resverlogix is a late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses and providing value-based health solutions to key partners.
-
Apabetalone
The world leader in a new class of drugs designed to regulate disease-associated epigenetics.
Learn More
-
Clinical Trials
BETonMACE – a global Phase 3 clinical trial with the most advanced epigenetic drug outside of oncology.
Learn More
-
Partnership Strategy
Providing novel science, clinical and value-based health solutions to key stakeholders, including payer groups.
Learn More
Investors
Resverlogix (TSX: RVX), founded in 2001 by Donald McCaffrey and Norman Wong, focuses on the development of therapeutics for disease states with high unmet medical need.
-
News Releases
- : Numerous Independent Groups Presented Data that Supports Apabetalone’s Potential Cardioprotective Benefits at European Society of Cardiology Congress 2024
- : Resverlogix Announces Voting Results from the 2024 Meeting of Shareholders and Closing of Debenture Extension
- : Resverlogix Announces Updated Annual and Special Meeting of Shareholders
View All
-
Financial Reports
View All
-
Presentations & Events
View All